Myeloid-derived Suppressor Cells in Gastrointestinal Cancers: A Systemic Review

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2021 Jan 29

PMID 33510845

Citations 14

Authors

Maham Farshidpour

Monjur Ahmed

Shilpa Junna

Juanita L Merchant

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal (GI) cancers are one of the most common malignancies worldwide, with high rates of morbidity and mortality. Myeloid-derived suppressor cells (MDSCs) are major components of the tumor microenvironment (TME). MDSCs facilitate the transformation of premalignant cells and play roles in tumor growth and metastasis. Moreover, in patients with GI malignancies, MDSCs can lead to the suppression of T cells and natural killer cells. Accordingly, a better understanding of the role and mechanism of action of MDSCs in the TME will aid in the development of novel immune-targeted therapies.

Citing Articles

Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer.

Cozac-Szoke A, Cozac D, Negovan A, Tinca A, Vilaia A, Cocuz I Int J Mol Sci. 2025; 26(3).

PMID: 39940924 PMC: 11818890. DOI: 10.3390/ijms26031156.

Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study).

Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N J Immunother Cancer. 2024; 12(11).

PMID: 39489543 PMC: 11535716. DOI: 10.1136/jitc-2024-010174.

The Link between Obesity and Gastrointestinal Cancers: a Short Review.

Akad F, Mocanu V, Filip B, Poroh M, Oboroceanu T, Akad N Maedica (Bucur). 2024; 19(2):360-364.

PMID: 39188821 PMC: 11345048. DOI: 10.26574/maedica.2024.19.2.360.

Photothermal treatment-based heat stress regulates function of myeloid-derived suppressor cells.

Lee M, Park S, Kim Y Sci Rep. 2024; 14(1):18847.

PMID: 39143087 PMC: 11324874. DOI: 10.1038/s41598-024-69074-3.

Impact of obesity‑associated myeloid‑derived suppressor cells on cancer risk and progression (Review).

Jimenez-Cortegana C, Gutierrez-Garcia C, Sanchez-Jimenez F, Vilarino-Garcia T, Flores-Campos R, Perez-Perez A Int J Oncol. 2024; 65(2).

PMID: 38940351 PMC: 11251741. DOI: 10.3892/ijo.2024.5667.

References

Chen M, Kuan F, Yen T, Lu M, Lin P, Chung Y . IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget. 2014; 5(18):8716-28. PMC: 4226716. DOI: 10.18632/oncotarget.2368. View

Xu J, Peng Y, Yang M, Guo N, Liu H, Gao H . Increased levels of myeloid-derived suppressor cells in esophageal cancer patients is associated with the complication of sepsis. Biomed Pharmacother. 2020; 125:109864. DOI: 10.1016/j.biopha.2020.109864. View

Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S . Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immunol Immunother. 2009; 59(5):697-706. PMC: 11030737. DOI: 10.1007/s00262-009-0786-4. View

Bordoni V, Sacchi A, Cimini E, Notari S, Grassi G, Tartaglia E . An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2272-2275. PMC: 7239202. DOI: 10.1093/cid/ciaa577. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Gabrilovich D, Ostrand-Rosenberg S, Bronte V . Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4):253-68. PMC: 3587148. DOI: 10.1038/nri3175. View

Hiraoka N, Onozato K, Kosuge T, Hirohashi S . Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12(18):5423-34. DOI: 10.1158/1078-0432.CCR-06-0369. View

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

Ma P, Beatty P, McKolanis J, Brand R, Schoen R, Finn O . Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol. 2019; 10:1401. PMC: 6594197. DOI: 10.3389/fimmu.2019.01401. View

10.

Diaz-Montero C, Finke J, Montero A . Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol. 2014; 41(2):174-84. PMC: 4008844. DOI: 10.1053/j.seminoncol.2014.02.003. View

11.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

12.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

13.

Najjar Y, Finke J . Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013; 3:49. PMC: 3597982. DOI: 10.3389/fonc.2013.00049. View

14.

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W . Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006; 203(12):2691-702. PMC: 2118163. DOI: 10.1084/jem.20061104. View

15.

Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G . Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016; 7(19):27676-88. PMC: 5053680. DOI: 10.18632/oncotarget.8507. View

16.

Lu L, Chang C, Hsu C . Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma. 2019; 6:71-84. PMC: 6511249. DOI: 10.2147/JHC.S159693. View

17.

Wang Z, Shen L . Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med. 2018; 4(1):1-7. PMC: 5938241. DOI: 10.1016/j.cdtm.2017.12.001. View

18.

Goh C, Roggerson K, Lee H, Golden-Mason L, Rosen H, Hahn Y . Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1. J Immunol. 2016; 196(5):2283-92. PMC: 4761460. DOI: 10.4049/jimmunol.1501881. View

19.

Merad M, Sathe P, Helft J, Miller J, Mortha A . The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013; 31:563-604. PMC: 3853342. DOI: 10.1146/annurev-immunol-020711-074950. View

20.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A . Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111(8):4233-44. DOI: 10.1182/blood-2007-07-099226. View